You should know that MEDX was in the backyard of BMY and that it was an easy deal because everybody knew each other. Not too many pharma and biotechs in Iowa so there would appear to be some difference but similar to the complaints in Israel that the biopharma companies sell out too early (as a result of regulatory and tax considerations) we hope that the incentives to sell out early are less attractive. However, Pancreatic cancer treatments seems at this point to have minimal competition and would be on the radar for most big pharmas looking to expand their oncology offerings.
Real tug of war on whether to stay independent. Time will tell.
Not before the Baker Brothers buy another boatload. They are mulling the next course of action and are positioning for greater upside. First you will see the BB purchase, then the upgrade and then the price will spike to about $50.